Clinical Trial Update: An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation [Phase 4]

View source ↗

Summary

Open-label, long-term Phase 4 study assessing immunogenicity ofLinaclotide (LINZESS) in adults with irritable bowel syndrome with constipation or chronic idiopa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Constipation
• Irritable Bowel Syndrome with Constipation

Drugs mentioned

• Linzess (linaclotide)

Snippet

Sponsor: Forest Laboratories | Conditions: Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation | Phase 4 | Status: COMPLETED | Results posted: 2019-08-22